Evidence map›Paper›PMID 33736629›Full record

ArticleBMC health services research2021

A feasibility study using time-driven activity-based costing as a management tool for provider cost estimation: lessons from the national TB control program in Zimbabwe in 2018.

J Chirenda, B Nhlema Simwaka, C Sandy, K Bodnar, S Corbin, P Desai, T Mapako, S Shamu, C Timire, E Antonio and 9 more

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

J ChirendaCollege of Health Sciences, Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe.
B Nhlema SimwakaThe Global Fund to Fight TB, HIV and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland. Bertha.Simwaka@theglobalfund.org.ORCID http://orcid.org/0000-0002-0134-4134
C SandyMinistry of Health and Child Care, National TB Control Program, Harare, Zimbabwe.
K BodnarHarvard Business School, Boston, MA, USA.
S CorbinThe Global Fund to Fight TB, HIV and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland.
P DesaiHarvard Business School, Boston, MA, USA.
T MapakoCollege of Health Sciences, Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe.
S ShamuCollege of Health Sciences, Department of Community Medicine, University of Zimbabwe, Harare, Zimbabwe.
C TimireMinistry of Health and Child Care, National TB Control Program, Harare, Zimbabwe.
E AntonioPrice Waterhouse Coopers (PWC), Harare, Zimbabwe.
A MakonePrice Waterhouse Coopers (PWC), Harare, Zimbabwe.
A BirikorangThe Global Fund to Fight TB, HIV and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland.
T MapurangaMinistry of Health and Child Care, National TB Control Program, Harare, Zimbabwe.
M NgwenyaWorld Health Organisation, Harare, Zimbabwe.
T MasundaMinistry of Health and Child Care, National TB Control Program, Harare, Zimbabwe.
M DubeMinistry of Health and Child Care, National TB Control Program, Harare, Zimbabwe.
E WandwaloThe Global Fund to Fight TB, HIV and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland.
L MorrisonThe Global Fund to Fight TB, HIV and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland.
R KaplanHarvard Business School, Boston, MA, USA.
Global Fund to Fight AIDS, Tuberculosis and Malaria · CHMinistry of Health and Child Welfare · ZWUniversity of Zimbabwe · ZWPricewaterhouseCoopers (Canada) · CAWorld Health Organization - Zimbabwe · ZW

Funding

Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)D43TW009539 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI METCALFE, JOHN ZAPATA · 2013 to 2022
$2.9M
FIC NIH HHS D43 TW009539Global Fund to Fight AIDS, Tuberculosis and Malaria Local Fund AgentWorld Health Organization 001
6 · The paper itself

Abstract

backgroundInsufficient cost data and limited capacity constrains the understanding of the actual resources required for effective TB control. This study used process maps and time-driven activity-based costing to document TB service delivery processes. The analysis identified the resources required to sustain TB services in Zimbabwe, as well as several opportunities for more effective and efficient use of available resources.

methodsA multi-disciplinary team applied time-driven activity-based costing (TDABC) to develop process maps and measure the cost of clinical pathways used for Drug Susceptible TB (DS-TB) at urban polyclinics, rural district and provincial hospitals, and community based targeted screening for TB (Tas4TB). The team performed interviews and observations to collect data on the time taken by health care worker-patient pairs at every stage of the treatment pathway. The personnel's practical capacity and capacity cost rates were calculated on five cost domains. An MS Excel model calculated diagnostic and treatment costs.

findingsTwenty-five stages were identified in the TB care pathway across all health facilities except for community targeted screening for TB. Considerable variations were observed among the facilities in how health care professionals performed client registration, taking of vital signs, treatment follow-up, dispensing medicines and processing samples. The average cost per patient for the entire DS-TB care was USD324 with diagnosis costing USD69 and treatment costing USD255. The average cost for diagnosis and treatment was higher in clinics than in hospitals (USD392 versus USD256). Nurses in clinics were 1.6 time more expensive than in hospitals. The main cost components were personnel (USD130) and laboratory (USD119). Diagnostic cost in Tas4TB was twice that of health facility setting (USD153 vs USD69), with major cost drivers being demand creation (USD89) and sputum specimen transportation (USD5 vs USD3).

conclusionTDABC is a feasible and effective costing and management tool in low-resource settings. The TDABC process maps and treatment costs revealed several opportunities for innovative improvements in the NTP under public health programme settings. Re-engineering laboratory testing processes and synchronising TB treatment follow-up with antiretroviral treatments could produce better and more uniform TB treatments at significantly lower cost in Zimbabwe.

Indexed as

Health Care CostsHospitalsFeasibility StudiesHumansTime FactorsZimbabwePathway to care cyclesProvider costTime driven activity-based costingTuberculosis

Identifiers

PMID33736629
PMCPMC7977596
OpenAlexW3136122931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.